Q4 2020 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Ladies and gentlemen, welcome to the Sobi presentation. (Operator Instructions)
I will now hand over to Guido Oelkers, CEO. Please go ahead.
()-&
Yes. Thank you so much, and welcome to the Q4 webcast of Sobi. As per usual, I go straight to the forward-looking statement, and we just take note of it, not going to read it through, but just be aware. Today, I'm going to be joined by my colleagues, Henrik Stenqvist, the CFO; and Ravi Rao, the Head of R&D.
And with this, let's go to the meet of the presentation on Slide 4. And basically, when you look at it, we had -- we have expanded our opportunity horizon for Sobi. I think it's fair to say that we are, this year -- that we have in 2020, but also in 2021, we are in a transition mode, and we are transitioning Sobi to a new reality.
And during this transition, we are experiencing headwinds, foremost COVID, and we will talk about this more in the context of the guidance for
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |